Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) Growth (1y) (2019 - 2026)
Esperion Therapeutics (ESPR) EPS (Weighted Average and Diluted) Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 72.22% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 5.97% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -12.22% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -94.22% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 2,287.50% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -15.38% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -407.69% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -300.00% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 76.47% |
| 10 | Esperion Therapeutics | 49.69 Mn | -118.16 Mn | 45.53 Mn | 52.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.38% |
| Dec 31, 2025 | 390.91% |
| Sep 30, 2025 | -6.67% |
| Jun 30, 2025 | 81.82% |
| Mar 31, 2025 | -161.76% |
| Dec 31, 2024 | 78.00% |
| Sep 30, 2024 | 59.46% |
| Jun 30, 2024 | 28.26% |
| Mar 31, 2024 | 143.04% |
| Dec 31, 2023 | 32.43% |
| Sep 30, 2023 | 54.32% |
| Jun 30, 2023 | 56.19% |
| Mar 31, 2023 | 15.05% |
| Dec 31, 2022 | 51.63% |
| Sep 30, 2022 | 69.08% |
| Jun 30, 2022 | 37.13% |
| Mar 31, 2022 | 73.43% |
| Dec 31, 2021 | 59.95% |
| Sep 30, 2021 | 14.66% |
| Jun 30, 2021 | -138.66% |